EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

The prognostic value of p53 and Ki-67 expression status in penile cancer: a systematic review and meta-analysis

Freja Lærke Sand, Sofie Lindquist, Gitte Lerche Aalborg, Susanne K Kjaer

Pathology · 2025-04 · 57 (3) · 276-284

DOI: 10.1016/j.pathol.2024.11.006 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Pathology, 2025-04. Verfasst von Freja Lærke Sand und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Virus, Lifestyle and Genes, Danish Cancer Institute, Strandboulevarden, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Ki-67 Antigen, Penile Neoplasms, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This meta-analysis aimed to explore penile cancer survival based on p53 and Ki-67 status. A systematic literature search identified studies assessing overall and cancer-specific survival after penile cancer with p53 or Ki-67 expression. Pooled hazard ratios (HRs) and restricted mean survival time (RMST) differences were calculated using a random-effects model. The analysis included 930 and 391 men for p53 expression in overall survival (OS) and cancer-specific survival (CSS), respectively. Those with the p53 mutant pattern exhibited significantly worse OS and CSS compared to the p53 wild-type pattern (HROS=2.42, 95% CI 1.75-3.34; HRCSS=4.18, 95% CI 1.87-9.35). The 5-year RMST difference for OS, according to p53 status, was -10.62 months (95% CI -16.20 to -5.03). We included 202 men with penile cancer tested for Ki-67 expression and found an HR of CSS of 1.96 (95% CI 1.15-3.32). In conclusion, men with the p53 mutant pattern penile cancer have worse OS and CSS than men with p53 wild-type pattern penile cancer. Evidence regarding Ki-67 status was sparse, but the pooled estimate indicated that penile cancers with high Ki-67 expression may have a slightly worse CSS than those with low Ki-67 expression. These findings may inform clinicians when planning the best management and follow-up strategy for penile cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorKi-67 AntigenPenile NeoplasmsTumor Suppressor Protein p53HumansMalePrognosis

Stichwörter der Autor:innen

Ki-67p53penile cancerprognostic markersurvival

Substanzen

Biomarkers, TumorKi-67 AntigenTP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Unit of Virus, Lifestyle and Genes, Danish Cancer Institute, Strandboulevarden, Copenhagen, Denmark.
  • Unit of Statistics and Data Analysis, Danish Cancer Institute, Strandboulevarden, Copenhagen, Denmark.
  • Unit of Virus, Lifestyle and Genes, Danish Cancer Institute, Strandboulevarden, Copenhagen, Denmark; Department of Gynecology, Rigshospitalet, University of Copenhagen, Blegdamsvej, Copenhagen, Denmark. Electronic addre…

Zitieren

APA

Sand, F. L., Lindquist, S., Aalborg, G. L., & Kjaer, S. K. (2025). The prognostic value of p53 and Ki-67 expression status in penile cancer: a systematic review and meta-analysis. Pathology, 57(3), 276-284. https://doi.org/10.1016/j.pathol.2024.11.006

Vancouver

Sand FL, Lindquist S, Aalborg GL, Kjaer SK. The prognostic value of p53 and Ki-67 expression status in penile cancer: a systematic review and meta-analysis. Pathology. 2025;57(3):276-284. doi:10.1016/j.pathol.2024.11.006

BibTeX
@article{Sand2025,
  author = {Sand, Freja Lærke and Lindquist, Sofie and Aalborg, Gitte Lerche and Kjaer, Susanne K},
  title = {The prognostic value of p53 and Ki-67 expression status in penile cancer: a systematic review and meta-analysis},
  journal = {Pathology},
  year = {2025},
  volume = {57},
  number = {3},
  pages = {276--284},
  doi = {10.1016/j.pathol.2024.11.006}
}
Kostenlos starten →